Key Highlights
- Florida's Attorney General sued Pfizer and CEO Albert Bourla, alleging deceptive marketing of its COVID-19 vaccine.
- The lawsuit claims Pfizer failed to disclose potential risks, including heart inflammation, while urging vaccination to protect others.
- Florida alleges Pfizer generated more than $80 billion in vaccine revenue before nearly quadrupling the dose price.
- The state is seeking civil penalties, injunctive relief, and the return of profits tied to the alleged conduct.
A Lawsuit Targeting Marketing and Pricing Practices
Florida Attorney General James Uthmeier filed a lawsuit against Pfizer (NYSE:PFE) and its Chairman and Chief Executive Officer, Albert Bourla, accusing the drugmaker of misleading consumers about the safety and effectiveness of its COVID-19 vaccine. The complaint, filed in state court, alleges that Pfizer told consumers its vaccine was safe while failing to disclose potential risks, including heart inflammation and other adverse events.
The lawsuit further alleges that Pfizer urged people to get vaccinated in order to protect others, even though the company had not tested whether the vaccine actually stopped transmission of the virus. Florida has also accused Pfizer of using unfair tactics to dominate the vaccine market.
Allegations of Suppressed Risk and Aggressive Pricing
According to the state's complaint, Pfizer orchestrated a wide-ranging marketing effort to maximize commercial adoption of its vaccine while obscuring emerging safety signals. The filing alleges that company commentary persistently reassured the public that no material safety risks existed, even as internal and external data pointed to elevated instances of myocarditis and pericarditis, particularly among younger men, along with potential reproductive risks and adverse event reports among elderly populations.
The complaint also contends that Pfizer actively promoted the vaccine as a tool to halt virus transmission despite lacking clinical trial data designed to measure transmission prevention specifically.
On the pricing side, Florida said Pfizer made more than $80 billion from vaccine sales before nearly quadrupling the price of a dose to between $110 and $130 in 2023, up from $30 previously, with private market prices reportedly reaching as high as $170. The state alleges Pfizer used tailor-made federal contracts to shield trade secrets and maintain pricing autonomy, which it says ultimately enabled the company to secure a dominant position in the vaccine market.
What Florida Is Seeking
Suing under its consumer protection law, Florida is seeking a court order to stop the alleged conduct, along with fines of $10,000 per violation, rising to $15,000 when violations involve harm to seniors or disabled individuals. The state is also seeking the return of profits tied to the alleged misconduct, along with permanent injunctive relief against further deceptive practices.
Florida's complaint contrasts Pfizer's initial $1.5 billion in self-funded research and development investment with the more than $80 billion in global COVID-19 vaccine revenue that followed, framing the disparity as evidence of a business model built around maximizing returns from a product the state alleges was marketed deceptively.
Pfizer Pushes Back
Pfizer said in a statement that the state's allegations "have no merit" and that the company would respond to the suit in due course. "The representations made by Pfizer about its COVID-19 vaccine have been accurate and science-based, and the company stands behind the safety and efficacy of its vaccine," the company said.
In response to a request for additional comment, Florida's Attorney General's Office said, "The complaint and comments by Florida Attorney General James Uthmeier speak for themselves."






Please wait processing your request...